The interplay between HPV and host immunity in head and neck squamous cell carcinoma

International Journal of Cancer

Volumn 134, Issue 12, 2014, Pages 2755-2763

  Andersen, Anne Skou ^a   Koldjær Sølling, Anne Sophie ^a   Ovesen, Therese ^a   Rusan, Maria ^a,b  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

Author keywords

head and neck squamous cell carcinoma; human papillomavirus; immune response; oropharyngeal squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; WART VIRUS VACCINE;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELLULAR IMMUNITY; DISEASE ASSOCIATION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HELPER CELL; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMORAL IMMUNITY; IMMUNOPATHOLOGY; IMMUNOTHERAPY; LYMPHOCYTIC INFILTRATION; MOUTH CARCINOMA; MOUTH INFECTION; NONHUMAN; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA; PALATINE TONSIL; PAPILLOMAVIRUS INFECTION; PHARYNX CARCINOMA; PREVALENCE; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; TONSIL DISEASE; TUMOR INVASION; UTERINE CERVIX CANCER; VIRUS CELL INTERACTION;

HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN PAPILLOMAVIRUS; IMMUNE RESPONSE; OROPHARYNGEAL SQUAMOUS CELL CARCINOMA;

ADAPTIVE IMMUNITY; CARCINOMA, SQUAMOUS CELL; EPITHELIUM; HEAD AND NECK NEOPLASMS; HUMAN PAPILLOMAVIRUS 16; HUMANS; OROPHARYNGEAL NEOPLASMS; OROPHARYNX; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; RISK FACTORS; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84897994499     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.28411     Document Type: Review

References (106)

1. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010; 363: 24-35.
2. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-9.
3. Sedaghat AR, Zhang Z, Begum S, et al. Prognostic significance of human papillomavirus in oropharyngeal squamous cell carcinomas. Laryngoscope 2009; 119: 1542-9.
4. Ragin CC, Taioli E,. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer 2007; 121: 1813-20.
5. Lassen P, Eriksen JG, Hamilton-Dutoit S, et al. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1992-8.
6. Lassen P, Eriksen JG, Krogdahl A, et al. The influence of HPV-associated p16-expression on accelerated fractionated radiotherapy in head and neck cancer: evaluation of the randomised DAHANCA 6&7 trial. Radiother Oncol 2011; 100: 49-55.
7. Sethi S, Ali-Fehmi R, Franceschi S, et al. Characteristics and survival of head and neck cancer by HPV status: a cancer registry-based study. Int J Cancer 2012; 131: 1179-86.
8. Sheth CH, Sharp S, Walters ER,. Enteral feeding in head and neck cancer patients at a UK cancer centre. J Hum Nutr Diet 2013. DOI: 10.1111/jhn.12029 (published online ahead of press).
9. Deboni AL, Giordani AJ, Lopes NN, et al. Long-term oral effects in patients treated with radiochemotherapy for head and neck cancer. Support Care Cancer 2012; 20: 2903-11.
10. Kenter GG, Welters MJ, Valentijn AR, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
11. Daayana S, Elkord E, Winters U, et al. Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia. Br J Cancer 2010; 102: 1129-36.
12. Doorbar J, Quint W, Banks L, et al. The biology and life-cycle of human papillomaviruses. Vaccine 2012; 30 (Suppl 5): F55-F70.
13. Kajitani N, Satsuka A, Kawate A, et al. Productive lifecycle of human papillomaviruses that depends upon squamous epithelial differentiation. Front Microbiol 2012; 3: 152.
14. Perry ME,. The specialised structure of crypt epithelium in the human palatine tonsil and its functional significance. J Anat 1994; 185 (Part 1): 111-27.
15. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313: 1960-4.
16. Nasman A, Romanitan M, Nordfors C, et al. Tumor infiltrating CD8+ and Foxp3+ lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PLoS One 2012; 7: e38711.
17. Nasman A, Andersson E, Nordfors C, et al. MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer 2013; 132: 72-81.
18. Watanabe Y, Katou F, Ohtani H, et al. Tumor-infiltrating lymphocytes, particularly the balance between CD8(+) T cells and CCR4(+) regulatory T cells, affect the survival of patients with oral squamous cell carcinoma. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2010; 109: 744-52.
19. Wansom D, Light E, Worden F, et al. Correlation of cellular immunity with human papillomavirus 16 status and outcome in patients with advanced oropharyngeal cancer. Arch Otolaryngol Head Neck Surg 2010; 136: 1267-73.
20. Turksma A, Bontkes H, van den Heuvel H, et al. Effector memory T-cell frequencies in relation to tumour stage, location and HPV status in HNSCC patients. Oral Dis 2013; 19: 577-84.
21. Thurlow JK, Pena Murillo CL, Hunter KD, et al. Spectral clustering of microarray data elucidates the roles of microenvironment remodeling and immune responses in survival of head and neck squamous cell carcinoma. J Clin Oncol 2010; 28: 2881-8.
22. Forman D, de Martel C, Lacey CJ, et al. Global burden of human papillomavirus and related diseases. Vaccine 2012; 30 (Suppl 5): F12-F23.
23. Gillison ML, Alemany L, Snijders PJ, et al. Human papillomavirus and diseases of the upper airway: head and neck cancer and respiratory papillomatosis. Vaccine 2012; 30 (Suppl 5): F34-F54.
24. Hoory T, Monie A, Gravitt P, et al. Molecular epidemiology of human papillomavirus. J Formos Med Assoc 2008; 107: 198-217.
25. Hebner CM, Laimins LA,. Human papillomaviruses: basic mechanisms of pathogenesis and oncogenicity. Rev Med Virol 2006; 16: 83-97.
26. Doorbar J,. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci 2006; 110: 525-41.
27. Lehoux M, D'Abramo CM, Archambault J,. Molecular mechanisms of human papillomavirus-induced carcinogenesis. Public Health Genomics 2009; 12: 268-80.
28. Stanley M,. Pathology and epidemiology of HPV infection in females. Gynecol Oncol 2010; 117: S5-S10.
29. Wilting SM, Smeets SJ, Snijders PJ, et al. Genomic profiling identifies common HPV-associated chromosomal alterations in squamous cell carcinomas of cervix and head and neck. BMC Med Genom 2009; 2: 32.
30. Pyeon D, Newton MA, Lambert PF, et al. Fundamental differences in cell cycle deregulation in human papillomavirus-positive and human papillomavirus-negative head/neck and cervical cancers. Cancer Res 2007; 67: 4605-19.
31. Lajer CB, Garnaes E, Friis-Hansen L, et al. The role of miRNAs in human papilloma virus (HPV)-associated cancers: bridging between HPV-related head and neck cancer and cervical cancer. Br J Cancer 2012; 106: 1526-34.
32. Guess JC, McCance DJ,. Decreased migration of Langerhans precursor-like cells in response to human keratinocytes expressing human papillomavirus type 16 E6/E7 is related to reduced macrophage inflammatory protein-3alpha production. J Virol 2005; 79: 14852-62.
33. Laurson J, Khan S, Chung R, et al. Epigenetic repression of E-cadherin by human papillomavirus 16 E7 protein. Carcinogenesis 2010; 31: 918-26.
34. Fausch SC, Fahey LM, Da Silva DM, et al. Human papillomavirus can escape immune recognition through Langerhans cell phosphoinositide 3-kinase activation. J Immunol 2005; 174: 7172-8.
35. Ronco LV, Karpova AY, Vidal M, et al. Human papillomavirus 16 E6 oncoprotein binds to interferon regulatory factor-3 and inhibits its transcriptional activity. Genes Dev 1998; 12: 2061-72.
36. Barnard P, Payne E, McMillan NA,. The human papillomavirus E7 protein is able to inhibit the antiviral and anti-growth functions of interferon-alpha. Virology 2000; 277: 411-19.
37. Park JS, Kim EJ, Kwon HJ, et al. Inactivation of interferon regulatory factor-1 tumor suppressor protein by HPV E7 oncoprotein. Implication for the E7-mediated immune evasion mechanism in cervical carcinogenesis. J Biol Chem 2000; 275: 6764-9.
38. Ashrafi GH, Haghshenas MR, Marchetti B, et al. E5 protein of human papillomavirus type 16 selectively downregulates surface HLA class I. Int J Cancer 2005; 113: 276-83.
39. Stanley M,. HPV-immune response to infection and vaccination. Infect Agents Cancer 2010; 5: 19.
40. de Gruijl TD, Bontkes HJ, Walboomers JM, et al. Analysis of IgG reactivity against human papillomavirus type-16 E7 in patients with cervical intraepithelial neoplasia indicates an association with clearance of viral infection: results of a prospective study. Int J Cancer 1996; 68: 731-8.
41. Bierl C, Karem K, Poon AC, et al. Correlates of cervical mucosal antibodies to human papillomavirus 16: results from a case control study. Gynecol Oncol 2005; 99: S262-S268.
42. Stanley M, Pinto LA, Trimble C,. Human papillomavirus vaccines-immune responses. Vaccine 2012; 30 (Suppl 5): F83-F87.
43. Nave H, Gebert A, Pabst R,. Morphology and immunology of the human palatine tonsil. Anat Embryol 2001; 204: 367-73.
44. Kim SH, Koo BS, Kang S, et al. HPV integration begins in the tonsillar crypt and leads to the alteration of p16, EGFR and c-myc during tumor formation. Int J Cancer 2007; 120: 1418-25.
45. Begum S, Cao D, Gillison M, et al. Tissue distribution of human papillomavirus 16 DNA integration in patients with tonsillar carcinoma. Clin Cancer Res 2005; 11: 5694-9.
46. Schreiber RD, Old LJ, Smyth MJ,. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-70.
47. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991-8.
48. Dunn GP, Old LJ, Schreiber RD,. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 2004; 21: 137-48.
49. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001; 410: 1107-11.
50. Koebel CM, Vermi W, Swann JB, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature 2007; 450: 903-7.
51. Zhou G, Lu Z, McCadden JD, et al. Reciprocal changes in tumor antigenicity and antigen-specific T cell function during tumor progression. J Exp Med 2004; 200: 1581-92.
52. DuPage M, Mazumdar C, Schmidt LM, et al. Expression of tumour-specific antigens underlies cancer immunoediting. Nature 2012; 482: 405-9.
53. Lin CT, Chang TC, Shaw SW, et al. Maintenance of CD8 effector T cells by CD4 helper T cells eradicates growing tumors and promotes long-term tumor immunity. Vaccine 2006; 24: 6199-207.
54. Spanos WC, Nowicki P, Lee DW, et al. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch Otolaryngol Head Neck Surg 2009; 135: 1137-46.
55. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008; 123: 187-94.
56. Tessari G, Girolomoni G,. Nonmelanoma skin cancer in solid organ transplant recipients: update on epidemiology, risk factors, and management. Dermatol Surg 2012; 38: 1622-30.
57. Leiding JW, Holland SM,. Warts and all: human papillomavirus in primary immunodeficiencies. J Allergy Clin Immunol 2012; 130: 1030-48.
58. Kreimer AR, Alberg AJ, Daniel R, et al. Oral human papillomavirus infection in adults is associated with sexual behavior and HIV serostatus. J Infect Dis 2004; 189: 686-98.
59. Shamanin V, zur Hausen H, Lavergne D, et al. Human papillomavirus infections in nonmelanoma skin cancers from renal transplant recipients and nonimmunosuppressed patients. J Natl Cancer Inst 1996; 88: 802-11.
60. de Sanjose S, Palefsky J,. Cervical and anal HPV infections in HIV positive women and men. Virus Res 2002; 89: 201-11.
61. Clemente CG, Mihm MC, Jr, Bufalino R, et al. Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer 1996; 77: 1303-10.
62. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 18538-43.
63. Kim ST, Jeong H, Woo OH, et al. Tumor-infiltrating lymphocytes, tumor characteristics, and recurrence in patients with early breast cancer. Am J Clin Oncol 2013; 36: 224-31.
64. Nosho K, Baba Y, Tanaka N, et al. Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-66.
65. Diederichsen AC, Hjelmborg J, Christensen PB, et al. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells. Cancer Immunol Immunother 2003; 52: 423-8.
66. Kawai O, Ishii G, Kubota K, et al. Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. Cancer 2008; 113: 1387-95.
67. Coussens LM, Werb Z,. Inflammation and cancer. Nature 2002; 420: 860-7.
68. Rollins BJ,. Inflammatory chemokines in cancer growth and progression. Eur J Cancer 2006; 42: 760-7.
69. Greten FR, Eckmann L, Greten TF, et al. IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell 2004; 118: 285-96.
70. Pikarsky E, Porat RM, Stein I, et al. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004; 431: 461-6.
71. Heusinkveld M, Goedemans R, Briet RJ, et al. Systemic and local human papillomavirus 16-specific T-cell immunity in patients with head and neck cancer. Int J Cancer 2012; 131: E74-E85.
72. Hoffmann TK, Arsov C, Schirlau K, et al. T cells specific for HPV16 E7 epitopes in patients with squamous cell carcinoma of the oropharynx. Int J Cancer 2006; 118: 1984-91.
73. Albers A, Abe K, Hunt J, et al. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck. Cancer Res 2005; 65: 11146-55.
74. Piersma SJ, Jordanova ES, van Poelgeest MI, et al. High number of intraepithelial CD8+ tumor-infiltrating lymphocytes is associated with the absence of lymph node metastases in patients with large early-stage cervical cancer. Cancer Res 2007; 67: 354-61.
75. Trimble CL, Clark RA, Thoburn C, et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010; 185: 7107-14.
76. Trimble CL, Peng S, Thoburn C, et al. Naturally occurring systemic immune responses to HPV antigens do not predict regression of CIN2/3. Cancer Immunol Immunother 2010; 59: 799-803.
77. Piersma SJ, Welters MJ, van der Hulst JM, et al. Human papilloma virus specific T cells infiltrating cervical cancer and draining lymph nodes show remarkably frequent use of HLA-DQ and -DP as a restriction element. Int J Cancer 2008; 122: 486-94.
78. de Vos, van Steenwijk PJ, Heusinkveld M, Ramwadhdoebe TH, et al. An unexpectedly large polyclonal repertoire of HPV-specific T cells is poised for action in patients with cervical cancer. Cancer Res 2010; 70: 2707-17.
79. de Jong A, van Poelgeest MI, van der Hulst JM, et al. Human papillomavirus type 16-positive cervical cancer is associated with impaired CD4+ T-cell immunity against early antigens E2 and E6. Cancer Res 2004; 64: 5449-55.
80. Steele JC, Mann CH, Rookes S, et al. T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia. Br J Cancer 2005; 93: 248-59.
81. Hobbs CG, Groves E, Davenport V, et al. Tonsil T cell immunity to human papillomavirus in the absence of detectable virus in healthy adults. Laryngoscope 2008; 118: 459-63.
82. Mork J, Lie AK, Glattre E, et al. Human papillomavirus infection as a risk factor for squamous-cell carcinoma of the head and neck. N Engl J Med 2001; 344: 1125-31.
83. Campoli M, Ferrone S,. HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance. Oncogene 2008; 27: 5869-85.
84. Vambutas A, DeVoti J, Pinn W, et al. Interaction of human papillomavirus type 11 E7 protein with TAP-1 results in the reduction of ATP-dependent peptide transport. Clin Immunol 2001; 101: 94-9.
85. Bais AG, Beckmann I, Lindemans J, et al. A shift to a peripheral Th2-type cytokine pattern during the carcinogenesis of cervical cancer becomes manifest in CIN III lesions. J Clin Pathol 2005; 58: 1096-100.
86. Sharma A, Rajappa M, Saxena A, et al. Cytokine profile in Indian women with cervical intraepithelial neoplasia and cancer cervix. Int J Gynecol Cancer 2007; 17: 879-85.
87. Clerici M, Merola M, Ferrario E, et al. Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. J Natl Cancer Inst 1997; 89: 245-50.
88. Xu Y, Zhu KJ, Zhu N, et al. Expression of Foxp3+CD4+CD25+ regulatory T cells and Th1/Th2, Tc1/Tc2 profiles in the peripheral blood of patients with condyloma acuminatum. Clin Exp Dermatol 2009; 34: 229-35.
89. Bonagura VR, Hatam L, DeVoti J, et al. Recurrent respiratory papillomatosis: altered CD8(+) T-cell subsets and T(H)1/T(H)2 cytokine imbalance. Clin Immunol 1999; 93: 302-11.
90. Visser J, Nijman HW, Hoogenboom BN, et al. Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia. Clin Exp Immunol 2007; 150: 199-209.
91. Smith EM, Pawlita M, Rubenstein LM, et al. Risk factors and survival by HPV-16 E6 and E7 antibody status in human papillomavirus positive head and neck cancer. Int J Cancer 2010; 127: 111-17.
92. Liang C, Marsit CJ, McClean MD, et al. Biomarkers of HPV in Head and Neck Squamous Cell Carcinoma. Cancer Res 2012; 72: 5004-13.
93. Furniss CS, McClean MD, Smith JF, et al. Human papillomavirus 16 and head and neck squamous cell carcinoma. Int J Cancer 2007; 120: 2386-92.
94. Isayeva T, Li Y, Maswahu D, et al. Human papillomavirus in non-oropharyngeal head and neck cancers: a systematic literature review. Head Neck Pathol 2012; 6 (Suppl 1): S104-S120.
95. Marklund L, Nasman A, Ramqvist T, et al. Prevalence of human papillomavirus and survival in oropharyngeal cancer other than tonsil or base of tongue cancer. Cancer Med 2012; 1: 82-8.
96. Ambs S, Marincola FM, Thurin M,. Profiling of immune response to guide cancer diagnosis, prognosis, and prediction of therapy. Cancer Res 2008; 68: 4031-3.
97. Ferris RL, Martinez I, Sirianni N, et al. Human papillomavirus-16 associated squamous cell carcinoma of the head and neck (SCCHN): a natural disease model provides insights into viral carcinogenesis. Eur J Cancer 2005; 41: 807-15.
98. Licitra L, Perrone F, Bossi P, Suardi S, Mariani L, Artusi R, Oggionni M, Rossini C, Cantù G, Squadrelli M, Quattrone P, Locati LD, Bergamini C, Olmi P, Pierotti MA, Pilotti S,. High-risk human papillomavirus affects prognosis in patients with surgically treated oropharyngeal squamous cell carcinoma. J Clin Oncol. 2006; 24: 5630-6 -. PubMed PMID: 17179101.
99. Nichols AC, Chan-Seng-Yue M, Yoo J, et al. A pilot study comparing HPV-positive and HPV-negative head and neck squamous cell carcinomas by whole exome sequencing. ISRN Oncol 2012; 2012: 809370.
100. Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science 2011; 333: 1157-60.
101. Apetoh L, Ghiringhelli F, Tesniere A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-9.
102. Rapidis AD, Wolf GT,. Immunotherapy of head and neck cancer: current and future considerations. J Oncol 2009; 2009: 346345.
103. Welters MJ, Kenter GG, de Vos van Steenwijk PJ, et al. Success or failure of vaccination for HPV16-positive vulvar lesions correlates with kinetics and phenotype of induced T-cell responses. Proc Natl Acad Sci USA 2010; 107: 11895-9.
104. Center SKCC. Safety study of HPV DNA vaccine to treat head and neck cancer patients, vol. 2013. ClinicalTrials. gov, 2012.
105. Institute NC. Vaccine therapy in treating patients with advanced or recurrent cancer, vol. 2013. ClinicalTrials.gov, 2012.
106. Liverpool Uo. Safety study of recombinant listeria monocytogenes(Lm)based vaccine virus vaccine to treat oropharyngeal cancer, vol. 2013. ClinicalTrials.gov, 2012.